Colibri Appoints Dr. Paul Bartos to Board of Directors and Grants Incentive Stock Options

VANCOUVER, July 18, 2011 /CNW/ - Colibri Resource Corporation ("Colibri" or the "Company") (TSX.V-CBI) is pleased to announce the appointment of Dr. Paul J. Bartos as Director.  Dr. Bartos is a noted authority on epithermal deposits and currently is the Vice President/ Chief Geologist of Esperanza Resources Corp. where he was instrumental in the discovery of the San Luis bonanza vein deposit.  This deposit, which was recently sold to Silver Standard Resources, has proven and probable reserves of 503,313 tonnes averaging 17.95 g/t Au, 446.14 g/t Ag (290,484 ounces gold, 7,219,435 ounces silver).  San Luis represents one of the highest grade precious metal deposits found in recent years.  Prior to this, Dr. Bartos was with ASARCO Inc., with his most recent position as Latin American Exploration and Business Development Manager.  Among other accomplishments, he was responsible for the discovery and development of the San Bartolome silver deposit in Bolivia.  This deposit, containing an estimated 107 million ounces of proven and probable silver reserves, is currently in production by Coeur d'Alene Mines Corp., and is now one of the world's largest pure silver mines.

In welcoming Dr. Bartos, Colibri CEO Lance Geselbracht said, "Dr. Bartos will be able to provide Colibri with valuable insights as we develop our Ramard Silver project and explore our other Sonora, Mexico properties. His past history in finding and developing ore bodies will help guide our exploration work.  Paul's experience with a very successful TSX Venture company provides us with additional insight to our own corporate development."

The Company also announces that a total of 950,000 options to purchase common shares of the Company have been granted to directors and officers at an exercise price of $0.25 per share, expiring on July 17, 2016. Any shares issued on the exercise of these stock options will be subject to a four-month hold period from date of grant. The grant is subject to regulatory approval.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.